公开(公告)号：WO2018098305A1

公开(公告)日：2018-05-31

申请号：PCT/US2017/063047

申请日：2017-11-22

申请人： EISAI R&D MANAGEMENT CO., LTD. ,  BOCK, Mark ,  HAO, Ming-Hong ,  KORPAL, Manav ,  NYAVANANDI, Vijay Kumar ,  PUYANG, Xiaoling ,  SAMAJDAR, Susanta ,  SMITH, Peter Gerard ,  WANG, John ,  ZHENG, Guo Zhu ,  ZHU, Ping ,  MITCHELL, Lorna Helen ,  LARSEN, Nicholas ,  RIOUX, Nathalie ,  PRAJAPATI, Sudeep ,  REYNOLDS, Dominic ,  O'SHEA, Morgan ,  SAMARAKOON, Thiwanka

发明人： BOCK, Mark ,  HAO, Ming-Hong ,  KORPAL, Manav ,  NYAVANANDI, Vijay Kumar ,  PUYANG, Xiaoling ,  SAMAJDAR, Susanta ,  SMITH, Peter Gerard ,  WANG, John ,  ZHENG, Guo Zhu ,  ZHU, Ping ,  MITCHELL, Lorna Helen ,  LARSEN, Nicholas ,  RIOUX, Nathalie ,  PRAJAPATI, Sudeep ,  REYNOLDS, Dominic ,  O'SHEA, Morgan ,  SAMARAKOON, Thiwanka

IPC分类号： C07D403/12 ,  C07D401/14 ,  C07D231/56 ,  C07D401/06 ,  A61P35/00 ,  A61K31/416

摘要： Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.

公开(公告)号：WO2018170129A1

公开(公告)日：2018-09-20

申请号：PCT/US2018/022437

申请日：2018-03-14

申请人： EISAI CO., LTD ,  WARMUTH, Markus ,  PUYANG, Xiaoling ,  TENG, Teng ,  ZHU, Ping

发明人： WARMUTH, Markus ,  PUYANG, Xiaoling ,  TENG, Teng ,  ZHU, Ping

IPC分类号： C12Q1/6886 ,  A61K31/7105

摘要： Spliceosome mutations are described herein, including mutations in the PHF5A and SF3B1 subunits. This application also describes detecting the presence and/or absence of mutations in the spliceosome, as well as methods of diagnosing responsiveness to splice modulator treatment, methods of treating neoplastic disorders, and methods of monitoring or altering the treatment based on mutation status.

公开(公告)号：WO2018098251A1

公开(公告)日：2018-05-31

申请号：PCT/US2017/062978

申请日：2017-11-22

申请人： EISAI R&D MANAGEMENT CO., LTD. ,  BOCK, Mark ,  HAO, Ming-Hong ,  KORPAL, Manav ,  NYAVANANDI, Vijay Kumar ,  PUYANG, Xiaoling ,  SAMAJDAR, Susanta ,  SMITH, Peter Gerard ,  WANG, John ,  ZHENG, Guo Zhu ,  ZHU, Ping ,  MITCHELL, Lorna Helen ,  LARSEN, Nicholas ,  RIOUX, Nathalie

发明人： BOCK, Mark ,  HAO, Ming-Hong ,  KORPAL, Manav ,  NYAVANANDI, Vijay Kumar ,  PUYANG, Xiaoling ,  SAMAJDAR, Susanta ,  SMITH, Peter Gerard ,  WANG, John ,  ZHENG, Guo Zhu ,  ZHU, Ping ,  MITCHELL, Lorna Helen ,  LARSEN, Nicholas ,  RIOUX, Nathalie

IPC分类号： C07D209/08 ,  A61P35/00

摘要： Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.